Pharmacokinetics of BPDO-1603 or BPDO-16031 and BPDO-16033 Administration in Healthy Adults

Phase 1 Completed 24 enrolled Hyundai Pharm

RandomizedCrossoverOpen-labelTreatment

Summary

Pharmacokinetics and safety of BPDO-1603 or BPDO-16031 and BPDO-16033 administration in healthy adults. Randomized, open-label, single-dose, cross-over, Phase 1 study

Timeline

Start: 2022-12-28
Primary completion: 2023-02-21
Completion: 2023-03-14

Publications

Choi M, Jin BH, Keum DH, Mo KH, Park MS, Lee J, Park S, Kim CO. Bioequivalence of a Donepezil/Memantine 10/20 mg Fixed-Dose Combination Versus Single-Component Tablets in Healthy Korean Males. Clin Pharmacol Drug Dev. 2025 Sep;14(9):710-716. doi: 10.1002/cpdd.1556. Epub 2025 May 30.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Donepezil	Small molecule	10 mg	Oral
Subject	Memantine	Unknown	20 mg	Oral

Indications

No indication recorded.